Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright has recently reiterated Microbot Medical Inc (MBOT) stock to Buy rating, as announced on January 13, 2020, according to Finviz. Earlier, on December 24, 2019, H.C. Wainwright had ...

https://www.tipranks.com/news/the-fly/monopar-therapeutics-price-target-raised-to-40-from-22-at-h-c-wainwright H.C. Wainwright raised the firm’s price target on ...

https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-raised-to-39-from-36-at-h-c-wainwright H.C. Wainwright raised the firm’s price target on ...